Tip os
Log ind
Bærbar scanner.jpg
Foto: DTU

New technology could revolutionize medtech firm’s business

Top picks in English:

Through the biggest project ever from Innovation Fund Denmark, researchers have developed an ultrasound scanning technology with the potential to transform the market. A medtech company involved in the project is now trying to figure out how to commercialize the invention.


BY LOUISE WENDT JENSEN
Offentliggjort 14.03.17 kl. 13:31

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Novo chief: ”This is data the world has never seen before”

Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Viagra copies cost less than 3 kroner

Top picks in English:

Since Viagra lost patent on June 24, 2013, generic versions of the drug have made the price drop by a staggering 97 %, according to a new analysis from a Danish pharmacy association. It could save Danish consumers millions per year.

Novo Nordisk shows ”extremely strong data” in obesity trial

Top picks in English:

Novo Nordisk leads the way when it comes to medical treatment of obesity. According to Sydbank analyst Søren Løntoft Hansen, the brand new results from a phase II clinical trial with pipeline jewel semaglutide more than meet FDA’s requirements for obesity drugs.

Saniona spins out cancer project in new firm

Top picks in English:

Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.

Leo’s bet on biologics progresses as planned

Top picks in English:

The biotech company Argenx has finished the preclinical work with the drug Leo Pharma invested in. Next stop is phase I “Our bet on biologics looks promising,” says Leo Pharma R&D chief.

Forsiden lige nu

Nye veje til kunderne skal skabe vækst i rehabselskab

Buus.jpg Medico & Rehab:

Det har været et stærkt år for rehabselskabet Vela, og nu skal selskabets netop lancerede treårsplan åbne for nye indgangsvinkler til kunderne og et yderligere løft i omsætningen.

AstraZeneca-boss var bedst betalte medicinalchef i 2016

Medicinal & Biotek:

Pascal Soriot fra Astrazeneca var i 2016 den europæiske medicinalchef, der kunne sætte det største beløb ind på kontoen, viser opgørelse.

MedWatch-indeks: Lundbeck til tops i nyhedsfattig uge

Medicinal & Biotek:

Både Novo Nordisk og Genmab høstede positiv omtale i ugens løb, men alligevel er det Lundbeck, der løber med denne uges topplacering i MedWatch-indekset.

Dansk medicoselskab går konkurs

Medico & Rehab:

Direktøren for LJ Medical Nordic havde satset på, at han kunne vende skuden i selskabet efter flere års svingende resultater, men de planer er ikke lykkes, og selskabet er nu meldt konkurs.

Sanofi indgår milliardaftale med Novo-partner

Medicinal & Biotek:

Den franske medicinalkoncern Sanofi har skrevet under på en aftale med et belgisk biotekselskab, som også arbejder sammen med Novo Nordisk. Aftalen har en potentiel værdi af flere milliarder.

Coloplast-konkurent køber ind i USA

Medico & Rehab:

En af Coloplasts konkurrenter, som Novo A/S for nyligt investerede i, har været ude og købe ind på det amerikanske marked for et trecifret millionbeløb.

ANNONCE
ANNONCE


ANNONCE